Yahoo
NasdaqCM - Delayed Quote USD

Starling Oncology, Inc. (STLNW)

0.0125 -0.0025 (-16.67%)
At close: November 6 at 4:00:00 PM EST
Chart Range Bar
Loading chart for STLNW
  • Previous Close 0.0150
  • Open 0.0185
  • Bid --
  • Ask --
  • Day's Range 0.0080 - 0.0185
  • 52 Week Range 0.0080 - 0.0185
  • Volume 84,972
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • 1y Target Est --
  • Moby Rating Neutral

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.

starlingoncology.com

641

Full Time Employees

--

Fiscal Year Ends

--

Sector

--

Industry

Recent News

View More

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 169.77M
Earnings -13.29M
Profit Margin -7.83%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
150M
-6.0%
-4.0%
-2.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.73%

  • Return on Assets (ttm)

    -7.48%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    620.45M

  • Net Income Avi to Common (ttm)

    -30.03M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    36.9M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    29.54M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: